BCL2L1 and acute lymphoblastic leukemia: Finally, the co-inhibition of BCL-2 and BCL-XL with a selective inhibitor (A-1155463), or by combining venetoclax and navitoclax, also resulted in the synergistic killing of ALL cells [26].